State Street’s OnKure Therapeutics OKUR Stock Holding History

State Street’s Portfolio OKUR Stock Details OKUR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$55.7K	Buy	+13,462	New	+$41.6K	﹤0.01%	4114
2024 Q4	–	Sell	-7,164	Closed	-$122K	–	4325
2024 Q3	$122K	Hold	7,164	–	–	﹤0.01%	3938
2024 Q2	$108K	Sell	7,164 -17,579	-71%	-$298K	﹤0.01%	3994
2024 Q1	$411K	Hold	24,743	–	–	﹤0.01%	3700
2023 Q4	$396K	Buy	24,743 +2,939	+13%	+$183K	﹤0.01%	3695
2023 Q3	$1.66M	Buy	21,804 +642	+3%	+$43.7K	﹤0.01%	3401
2023 Q2	$1.39M	Buy	21,162 +19,522	+1,190%	+$1.57M	﹤0.01%	3524
2023 Q1	$98.1K	Hold	1,640	–	–	﹤0.01%	4332
2022 Q4	$38.2K	Hold	1,640	–	–	﹤0.01%	4619
2022 Q3	$55K	Hold	1,640	–	–	﹤0.01%	4636
2022 Q2	$43K	Sell	1,640 -7,285	-82%	-$170K	﹤0.01%	4751
2022 Q1	$262K	Buy	8,925 +119	+1%	+$6.66K	﹤0.01%	4290
2021 Q4	$753K	Buy	8,806 +205	+2%	+$15.1K	﹤0.01%	3881
2021 Q3	$641K	Buy	8,601 +2,509	+41%	+$213K	﹤0.01%	3894
2021 Q2	$568K	Buy	+6,092	New	+$679K	﹤0.01%	3810

Other funds holding OKUR

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

FCMV

Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street's OKUR Position: Q1 2026 in Review

State Street opened a new position in OnKure Therapeutics (OKUR) in Q1 2026: 13,462 shares worth $55.7K. The stake represents ﹤0.01% of the portfolio and ranks #4114 among its holdings. This is a return to the name: State Street previously reported a position in OKUR as recently as Q3 2024.

State Street first reported a position in OKUR in Q2 2021 and has held it in 15 quarters since. The position peaked at $1.66M in Q3 2023. 51 funds tracked by Wall St. Rank hold OKUR as of Q1 2026.

State Street held 13,462 shares of OnKure Therapeutics worth $55.7K as of Q1 2026.
OnKure Therapeutics was a new State Street position in Q1 2026.
OnKure Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #4114 holding.
State Street first reported a position in OnKure Therapeutics in Q2 2021 and has held it in 15 quarters since.
State Street's OnKure Therapeutics position peaked at $1.66M in Q3 2023.
51 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.